Activity of mitochondrial respiratory chain is increased by chronic administration of antidepressants

Acta Neuropsychiatrica

Volumn 23, Issue 3, 2011, Pages 112-118

  Scaini, Giselli ^a,b   Maggi, Débora D ^a,b   De Nês, Bruna T ^a,b   Gonçalves, Cinara L ^a,b   Ferreira, Gabriela K ^a,b   Teodorak, Brena P ^a,b   Bez, Gisele D ^a,b   Ferreira, Gustavo C ^c   Schuck, Patricia F ^a,b   Quevedo, João ^a,b   Streck, Emilio L ^a,b  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b Instituto Nacional de Ciencia e Tecnologia Translacional em Medicina   (Brazil)

^c UNIVERSITY OF SOUTHERN SANTA CATARINA   (Brazil)

Author keywords

brain; mitochondrial respiratory chain; nortriptyline; paroxetine; venlafaxine

Indexed keywords

CYTOCHROME C OXIDASE; NORTRIPTYLINE; PAROXETINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUCCINATE DEHYDROGENASE (UBIQUINONE); UBIQUINOL CYTOCHROME C REDUCTASE; VENLAFAXINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CELL ACTIVITY; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DECAPITATION; ELECTROENCEPHALOGRAM; ENERGY METABOLISM; HIPPOCAMPUS; MAJOR DEPRESSION; MALE; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL RESPIRATORY CHAIN; NONHUMAN; PREFRONTAL CORTEX; RAT; RESPIRATORY CHAIN;

EID: 79957508799     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2011.00548.x     Document Type: Article

References (56)

1. Kessler RC, Walters EE., Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey. Depress Anxiety 1998; 7: 3-14. (Pubitemid 28248515)
2. Turner JR, Gil AG., Psychiatric and substance use disorders in South Florida racial/ethnic and gender contrasts in a young adult cohort. Arch Gen Psychiatry 2002; 59: 43-50. (Pubitemid 34044404)
3. Kessler RC, Berglund P, Demler O, Jin R, Merikans KR, Walters EE., Lifetime prevalence and age-of-onset distributions of DSM-IV disorder in the national comorbidity survey replication. Arch Gen Psychiatry 2005; 62: 593-768.
4. Murphy JM, Laird NM, Monson RR, Sobol AM, Leighton AH., 40-year perspective on the prevalence of depression. The Stirling County Study. Arch Gen Psychiatry 2000; 57: 209-215. (Pubitemid 30140428)
5. World Health Organization (WHO). 2009. Programmes and projects/mental health/disorders management/depression. URL [accessed on 1 March 2010].
6. Skolnick P., Beyond monoamine-based therapies: clues to new approaches. J Clin Psychiatry 2002; 63: 19-23. (Pubitemid 34208793)
7. Charney DS., Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59: 11-14. (Pubitemid 28462383)
8. Castrén E., Is mood chemistry? Nat Rev Neurosci 2005; 6: 241-246. (Pubitemid 40342418)
9. Shelton RC., The molecular neurobiology of depression. Psychiatr Clin N Am 2007; 30: 1-11. (Pubitemid 46386302)
10. Krishnan V, Nestler EJ., The molecular neurobiology of depression. Nature 2008; 894-902.
11. Zarate Jr CA, Singh JB, Carlson PJ, et al., A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-64. (Pubitemid 44188478)
12. Millan MJ., Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 2006; 110: 135-370.
13. Baghai TC, Grunze H, Sartorius N., Antidepressant medications and other treatments of depressive disorders: a CINP task force report based on a review of evidence. Int J Neuropsychopharmacol 2007; 10: S1-S207.
14. Morilak DA, Frazer A., Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. Int J Neuropsychopharmacol 2007; 7: 193-218. (Pubitemid 38823288)
15. Johnson AM., Paroxetine: A pharmacological review. Int Clin Psychopharmacology 1992; 6: 15-24.
16. Richelson E., Pharmacology of anti-depressants-characteristics of the ideal drug. Mayo Clin Proc 1999; 69: 1069-1081.
17. Duman RS, Heninger GR, Nestler EJ., A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606. (Pubitemid 27306570)
18. Calabrese V, Scapagnini G, Giuffrida-Stella AM, Bates TE, Clark JB., Mitochondrial involvement in brain function and dysfunction: relevance to aging, neurodegenerative disorders and longevity. Neurochem Res 2001; 26: 739-764. (Pubitemid 32756837)
19. Horn D, Barrientos A., Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life 2008; 60: 421-429.
20. Blass JP., Brain metabolism and brain disease: is metabolic deficiency the proximate cause of Alzheimer dementia? J Neurosci Res 2001; 66: 851-856.
21. Brennan WA, Bird ED, Aprille JR., Regional mitochondrial respiratory activity in Huntington's disease brain. J Neurochem 1985; 44: 1948.
22. Heales SJ, Bolanõs JP, Stewart VC, Brookes PS, Land JM, Clark JB., Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta 1999; 1410: 215-228. (Pubitemid 29078606)
23. Schurr A., Energy metabolism, stress hormones and neural recovery from cerebral ischemia/hypoxia. Neurochem Int 2002; 41: 1-8. (Pubitemid 34251400)
24. Monsalve M, Borniquel S, Valle I, Lamas S., Mitochondrial dysfunction in human pathologies. Front Biosci 2007; 12: 1131-1153. (Pubitemid 46850646)
25. Moreira PI, Santos MS, Oliveira CR., Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid Redox Signal 2007; 9: 1621-1630. (Pubitemid 47462966)
26. Moreira PI, Santos MS, Seiça R, Oliveira CR., Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 2007; 257: 206-214. (Pubitemid 46856489)
27. Tretter L, Mayer-Takacs D, Adam-Vizi V., The effect of bovine serum albumin on the membrane potential and reactive oxygen species generation in succinate-supported isolated brain mitochondria. Neurochem Int 2007; 50: 139-147. (Pubitemid 44895358)
28. Petrosillo G, Matera M, Casanova G, Ruggiero FM, Paradies G., Mitochondrial dysfunction in rat brain with aging: involvement of complex I, reactive oxygen species and cardiolipin. Neurochem Int 2008; 53: 126-131.
29. Kanarik M, Matrov D, Kõiv K, Eller M, Tõnissaar M, Harro J., Changes in regional long-term oxidative metabolism induced by partial serotonergic denervation and chronic variable stress in rat brain. Neurochem Int 2008; 52: 432-437.
30. Stanyer L, Jorgensen W, Hori O, Clark JB, Heales SJ., Inactivation of brain mitochondrial Lon protease by peroxynitrite precedes electron transport chain dysfunction. Neurochem Int 2008; 53: 95-101.
31. Nestler EJ, McMahon A, Sabban EL, Tallman JF, Duman RS., Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci U S A 1990; 87: 7522-7526. (Pubitemid 20341748)
32. Berrocoso E, Rojas-Corrales MO, Micõ JA., Non- selective opioid receptor antagonism of the antidepressant-like effect of venlafaxine in the forced swimming test in mice. Neurosci Lett 2004; 363: 25-28. (Pubitemid 38639845)
33. Casarotto PC, Andreatini R., Repeated paroxetine treatment reverses anhedonia induced in rats by chronic mild stress or dexamethasone. Eur Neuropsychopharmacol 2007; 17: 735-742. (Pubitemid 47432838)
34. Drapier D, Bentué-Ferrer D, Laviolle B, Millet B, Allain H, Bourin M, Reymann JM., Effects of acute fluoxetine, paroxetine and desipramine on rats tested on the elevated plus-maze. Behav Brain Res 2007; 176: 202-209. (Pubitemid 44880083)
35. Ide S, Fujiwara S, Fujiwara M, et al., Antidepressant-like effect of venlafaxine is abolished in μ-opioid receptor-knockout mice. J Pharmacol Sci 2010; 114: 107-110.
36. Lowry OH, Rosebough NG, Farr AL, Randall RJ., Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
37. Cassina A, Radi R., Differential inhibitory Aation of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys 1996; 328: 309-316. (Pubitemid 26160113)
38. Fischer JC, Ruitenbeek W, Berden JA, et al., Differential investigation of the capacity of succinate oxidation in human skeletal muscle. Clin Chim Acta 1985; 153: 23-26. (Pubitemid 16200073)
39. Rustin P, Chretien D, Bourgeron T, et al., Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228: 35-51. (Pubitemid 24231224)
40. Rex A, Schickert R, Fink H., Antidepressant-like effect of nicotinamide adenine dinucleotide in the forced swim test in rats. Pharmacol Biochem Behav 2004; 77: 303-307. (Pubitemid 38125162)
41. Boekema EJ, Braun HP., Supramolecular structure of the mitochondrial oxidative phosphorylation system. J Chem Biol 2007; 282: 1-4. (Pubitemid 47076588)
42. Fattal O, Budur K, Vaughan AJ, Franco K., Review of the literature on major mental disorders in adult patients with mitochondrial diseases. Psychosomatics 2006; 47: 1-7. (Pubitemid 43017115)
43. Madrigal JL, Olivenza R, Moro M, et al., Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology 2001; 24: 420-429. (Pubitemid 32157558)
44. Gardner A, Johansson A, Wibom R, et al., Alterations of mitochondrial function and correlations with personality traits in selected major depressive disorder patients. J Affect Disord 2003; 76: 55-68. (Pubitemid 37013356)
45. +-ATPase activity in rats subjected to an experimental model of depression. Neurochem Res 2003; 28: 1339-1344. (Pubitemid 38113062)
46. Rezin GT, Cardoso MR, Gonçalves CL, et al., Inhibition of mitochondrial respiratory chain in brain of rats subjected to an experimental model of depression. Neurochem Int 2008; 53: 395-400.
47. Assis LC, Rezin GT, Comim CM, et al., Effect of acute administration of ketamine and imipramine on creatine kinase activity in the brain of rats. Rev Bras Psiquiatr 2009; 31: 247-252.
48. Santos PM, Scaini G, Rezin GT, et al., Brain creatine kinase activity is increased by chronic administration of paroxetine. Brain Res Bull 2009; 80: 327-330.
49. Scaini G, Santos PM, Benedet J, et al., Evaluation of Krebs cycle enzymes in the brain of rats after chronic administration of paroxetine. Brain Res Bull 2010; 82: 224-227.
50. Consoni FT, Vital MA, Andreatini R., Dual monoamine modulation for the antidepressant-like effect of lamotrigine in the modified forced swimming test. Eur Neuropsychopharmacol 2006; 16: 451-458. (Pubitemid 43996884)
51. Krass M, Wegener G, Vasar E, Volke V., The antidepressant action of imipramine and venlafaxine involves suppression of nitric oxide synthesis. Behav Brain Res 2011; 218: 57-63.
52. Streck EL, Feier G, Búrigo M, et al., Effects of electroconvulsive seizures on Na+, K+-ATPase activity in the rat hippocampus. Neurosci Lett 2006; 404: 254-257. (Pubitemid 44108432)
53. Búrigo M, Roza CA, Bassani C, et al., Decreased creatine kinase activity caused by electroconvulsive shock. Neurochem Res 2006; 31: 877-881. (Pubitemid 44134240)
54. Kálmán J, Palotás A, Juhász A, et al., Impact of venlafaxine on gene expression profile in lymphocytes of the elderly with major depression-evolution of antidepressants and the role of the "neuro-immune" system. Neurochem Res 2005; 30: 1429-1438. (Pubitemid 41784479)
55. Piubelli C, Gruber S, El Khoury A, Mathé AA, Domenici E, Carboni L., Nortriptyline influences protein pathways involved in carbohydrate metabolism and actin-related processes in a rat gene-environment model of depression. Eur Neuropsychopharmacol 2010. [E-pub ahead of print; DOI:10.1016/j.euroneuro.2010.11.003]
56. McHugh PC, Rogers GR, Loudon B, Glubb DM, Joyce PR, Kennedy MA,. Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. J Neurosci Res 2008; 86: 306-316. (Pubitemid 351196736)